Our leadership team has studied hepatitis in great research institutes, dirt-floored clinics and, in one case, in his own body.
Board of Directors
|
|
 |
 |
|
|
|
|
 |
 |
 |
|
|
|
|
 |
 |
|
|
Carol Tissot, Secretary and General Counsel |
ZeShan Foundation, Observer |
 |
 |
|
Executive Director |
Director Programme and Partnerships |
|
|
|
|
Senior Advisor External Relations and Operations Coordinator |
Senior Program Officer, Grants and M&E |
Advisory Council
The scope of The Hepatitis Fund’s activities spans numerous hepatitis prevention and care interventions that target different populations in a wide range of geographical settings. Members of the Advisory Council have expertise in key programmatic aspects of hepatitis prevention and care, are representative of the key populations affected by hepatitis and of regions heavily affected by hepatitis.
 |
 |
 |
| Joan Block – retired executive director, Hepatitis B Foundation |
Saeed Hamid– co-chair, Coalition to Eradicate Viral Hepatitis in Asia Pacific | Homie Razavi– executive director, Center for Disease Analysis Foundation |
 |
 |
 |
| Lewis Roberts -director, Gastroenterology and Hepatology Cancer Center at the Mayo Clinic | Shin Young-Soo -director emeritus, WHO Western Pacific Regional Office | Su Wang– Medical Director, Viral Hepatitis Programs |
|
||
| ZeShan Foundation |
Steering and Oversight Committees
We thank members of the EndHep2030 steering committee and oversight committee who supported the emergence of this initiative.
The Hepatitis Fund wishes to extend a heartfelt thank you to its past President and co-Founder, Mr Wangsheng LI, for leading The Hepatitis Fund through numerous changes and challenges these past two and a half years. Mr LI exhibited vision and passion throughout his term and we wish him every success in his future endeavours.
Oversight Committee members
The Oversight Committee was active from November 2017 - December 2019. It was created as the managing body for EndHep2030 as an RPA-sponsored project.
Steering Committe members
The Steering Committee was created to stand up the EndHep2030 project. It was in commission from November 2016 through October 2017. The Steering Committee accomplished its mandate upon the launch of EndHep2030 in 2017.
Manal El-Sayed
Professor of Pediatrics at Ain Shams University.
Marc Bulterys
Director
WHO Global Hepatitis Programme
Charles Gore
Executive Director
Medicines Patent Pool
Charles Gore
Executive Director
Medicines Patent Pool
Jinlin Hou
Chairman and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University.
Rana Hajjeh
Director
Department of Communicable Disease Prevention and Control,
WHO Regional Office for the Eastern Mediterranean
Paul Kuehnert
Vice President, Program
Robert Woods Johnson Foundation
Ying-ru Jacqueline Lo
Team Lead
HIV, Hepatitis & STD, WHO Western Pacific Regional Office
Paul Kuehnert
Vice President, Program
Robert Woods Johnson Foundation
Lillian Lou
Executive Director
The John C. Martin Foundation
Tony Lee
Director and Partner
Social Sector Practice, McKinsey & Company
Judith Monroe
president and CEO of the CDC Foundation.
Nicole M. Smith
Associate Director for Policy & Communication for the Division of Viral Hepatitis at the U.S. CDC.
Isabelle Mayer-Andrieux
Viral Hepatitis Advisor
Médecins Sans Frontières
Annette Sohn
Executive Director
TreatAsia, amfAR
Kathrine Meyers
Director for China Program
Aaron Diamond AIDS Research Center at the Rockefeller University
Mike van der Ven
Director
Pivotal Ventures, Bill and Melinda Gates Foundation
Nick Walsh
Medical Officer (Viral Hepatitis)
WHO Consultant
Stefan Wiktor
Founding Director (retired)
WHO Global Hepatitis Programme
John Ward
Director
Coalition for Global Hepatitis Elimination
David Wilson
Program director, World Bank’s Health, Population and Nutrition global practice.